Trial Profile
Multiple-Dose Efficacy and Safety Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Arbaclofen placarbil (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- Sponsors XenoPort
- 16 Sep 2014 New trial record